Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Icon ( (ICLR) ) just unveiled an announcement.
ICON plc reported its financial results for the first quarter of 2025, highlighting net business wins of $2,022 million and a closing backlog of $24.7 billion. Despite facing challenges such as customer decision-making delays and elevated cancellations, the company maintained an adjusted EBITDA margin and earnings per share in line with expectations. Revenue for the quarter was $2,001.3 million, a decrease from the previous year, and GAAP net income was $154.2 million. ICON updated its full-year 2025 financial guidance, excluding two large COVID vaccine trials, and anticipates revenue between $7,750 and $8,150 million. The company continues to focus on resource management to deliver critical development programs.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall score reflects its robust financial performance and reasonable valuation, tempered by technical weakness and mixed earnings call results. The company’s strengths lie in its profitability and strategic management, though market challenges and technical indicators present risks.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a leading clinical research organization based in Dublin, Ireland, specializing in outsourced services for pharmaceutical, biotechnology, medical device, and government and public health organizations. With a focus on advancing clinical research from molecule to medicine, ICON employs approximately 41,250 people across 97 locations in 55 countries.
YTD Price Performance: -31.81%
Average Trading Volume: 1,158,952
Technical Sentiment Signal: Buy
Current Market Cap: $11.71B
See more data about ICLR stock on TipRanks’ Stock Analysis page.